Research programme: respiratory syncytial virus vaccine - GenVecAlternative Names: GV-2311; RSV vaccine - GenVec
Latest Information Update: 17 Nov 2014
At a glance
- Originator GenVec
- Developer GenVec; National Institute of Allergy and Infectious Diseases
- Class Viral vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Respiratory syncytial virus infections